Circulating Fibroblast Growth Factor-23 Is Associated With Fat Mass and Dyslipidemia in Two Independent Cohorts of Elderly Individuals | Zendy

Majd A.I. Mirza | Zendy; Johan Alsiö | Zendy; Ann Hammarstedt | Zendy; Reinhold G. Erben | Zendy; Karl Michaëlsson | Zendy; Åsa Tivesten | Zendy; Richard Marsell | Zendy; Eric Orwoll | Zendy; Magnus K. Karlsson | Zendy; Östen Ljunggren | Zendy; Dan Mellström | Zendy; Lars Lind | Zendy; Claes Ohlsson | Zendy; Tobias E. Larsson | Zendy

Open Access

Circulating Fibroblast Growth Factor-23 Is Associated With Fat Mass and Dyslipidemia in Two Independent Cohorts of Elderly Individuals

Author(s) -

Majd A.I. Mirza,

Johan Alsiö,

Ann Hammarstedt,

Reinhold G. Erben,

Karl Michaëlsson,

Åsa Tivesten,

Richard Marsell,

Eric Orwoll,

Magnus K. Karlsson,

Östen Ljunggren,

Dan Mellström,

Lars Lind,

Claes Ohlsson,

Tobias E. Larsson

Publication year - 2010

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.110.214619

Subject(s) - medicine , endocrinology , waist , fibroblast growth factor 23 , body mass index , risk factor , dyslipidemia , obesity , lipid metabolism , parathyroid hormone , calcium

Disturbances in mineral metabolism define an increased cardiovascular risk in patients with chronic kidney disease. Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has recently been implicated as a putative pathogenic factor in cardiovascular disease. Because other members of the FGF family play a role in lipid and glucose metabolism, we hypothesized that FGF23 would associate with metabolic factors that predispose to an increased cardiovascular risk. The goal of this study was to investigate the relationship between FGF23 and metabolic cardiovascular risk factors in the community.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research